Table 2.
NCCN Treatment Guidelines for mRCC, by Phase 3 Evidence
| Setting | Category 1 evidence | |
|---|---|---|
| Treatment naïve | Good or intermediate riska | Sunitinib Pazopanib Bevacizumab + IFN-α |
| Poor riska | Temsirolimus | |
| Previously treated | Previous cytokine | Sorafenib Sunitinib Pazopanib Axitinibb |
| Previous tyrosine kinase inhibitor | Everolimus Axitinibb |
|
| Previous mTOR inhibitor | Unknown | |
a
Memorial Sloan-Kettering Cancer Center risk category.
b
Axitinib has a category 1 recommendation for treatment of patients who have failed ≥1 previous systemic therapy.
IFN indicates interferon; mRCC, metastatic renal cell carcinoma; mTOR, mammalian target of rapamycin; NCCN, National Comprehensive Cancer Network.
Source: National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Kidney cancer. Version 1.2013. 2013.